J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down

Johnson & Johnson’s Q3 2026 adjusted EPS was $2.59 versus $2.53 consensus, while revenue of $25.4 billion narrowly missed the $25.44 billion estimate; sales rose 5.9% year over year. Innovative Medicine sales grew 7.7%, led by Tremfya and newer therapies, but MedTech revenue of $8.64 billion fell short of the $8.77 billion estimate, and Stelara sales dropped 54.4% to $716 million amid biosimilar competition. J&J raised its 2026 sales guidance to $101.0-$101.4 billion and adjusted EPS guidance to $11.05-$11.15, yet shares fell around 2% in pre-market trading.

Analysis

The key issue is conversion, not the headline beat: raised sales guidance alongside comparatively modest adjusted-EPS growth leaves execution on margins, mix and deal-related costs as the test for whether JNJ’s growth is genuinely accretive. Verify segment profitability and acquisition-related expense before extrapolating the guide raise into earnings momentum. The talc-related reported-earnings distortion is a poor read-through to recurring operations, but settlement execution remains a separate event risk.

The market may be over-weighting a single weak MedTech quarter, yet the Impella concern is more consequential than ordinary procedure timing: if physician caution persists, it could constrain adoption beyond the quarter and weaken the expected recovery. Conversely, strong newer-drug demand and Tremfya’s contribution are helping absorb Stelara erosion; the risk is that a concentrated set of products must keep compounding while additional legacy products face generic or biosimilar pressure.

Biosimilar entrants including Amgen, Teva and Sandoz have a volume opportunity, but launch participation alone does not establish attractive economics: price competition and contracting can dilute the revenue benefit. JNJ’s recent relative outperformance also raises the bar for continued delivery. Over 1–3 months, watch MedTech growth, Impella procedure trends, and guidance changes; over 6–18 months, monitor whether new-drug growth offsets exclusivity losses without sacrificing margins.

Key Decisions for Investors

• Do not chase the guidance raise. Consider a tactical underweight in JNJ versus a diversified healthcare benchmark if the next update shows MedTech still failing to reaccelerate or adjusted EPS conversion weakening; cover/reassess if MedTech growth improves and management sustains guidance.
• Treat the approximately 2% post-results decline as insufficient by itself to establish a durable downside trend. For an existing JNJ position, use the next quarter’s MedTech growth and segment margins as the thesis checkpoint rather than reported EPS distorted by special items.
• Keep AMGN, TEVA and SDZ on a biosimilar watchlist, not as an automatic long: verify product-level launch sales, market share, pricing and contribution economics before sizing exposure. Broad price erosion or limited uptake would falsify the near-term beneficiary thesis.
• Key downside catalysts are persistent Impella-related physician caution, further legacy-drug erosion, or a guide reduction; upside catalysts are demonstrable MedTech recovery and continued new-product growth translating into stronger adjusted earnings.